Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria, Australia.
Subcell Biochem. 2021;97:375-392. doi: 10.1007/978-3-030-67171-6_14.
Extracellular vesicles (EVs) are lipid bilayer containing nanovesicles that have a predominant role in intercellular communication and cargo delivery. EVs have recently been used as a means for drug delivery and have been depicted to elicit no or minimal immune response in vivo. The stability, biocompatibility and manipulatable tumour homing capabilities of these biological vessels make them an attractive target for the packaging and delivery of drugs and molecules to treat various diseases including cancer. The following chapter will summarise current EV engineering techniques for the purpose of delivering putative drugs and therapeutic molecules for the treatment of cancer. The relevance of EV source will be discussed, as well as the specific modifications required to manufacture them into suitable vehicles for molecular drug delivery. Furthermore, methods of EV cargo encapsulation will be evaluated with emphasis on intercellular coordination to allow for the effective emptying of therapeutic contents into target cells. While EVs possess properties making them naturally suitable nanocarriers for drugs and molecules, many challenges with clinical translation of EV-based platforms remain. These issues need to be addressed in order to harness the true potential of the EV-based therapeutic avenue.
细胞外囊泡(EVs)是一种含有脂质双层的纳米囊泡,在细胞间通讯和货物传递中起主要作用。EVs 最近被用作药物递送的一种手段,并且在体内被描述为不会引起或很少引起免疫反应。这些生物载体的稳定性、生物相容性和可操控的肿瘤归巢能力使它们成为包装和递送至各种疾病(包括癌症)的药物和分子的有吸引力的目标。本章将总结目前用于递送潜在药物和治疗性分子以治疗癌症的 EV 工程技术。将讨论 EV 来源的相关性,以及将其制成适合分子药物递送的载体所需的特定修饰。此外,还将评估 EV 货物包封的方法,重点是细胞间协调,以允许将治疗性内容物有效排空到靶细胞中。虽然 EV 具有使其成为药物和分子天然合适的纳米载体的特性,但基于 EV 的平台在临床转化方面仍存在许多挑战。为了充分发挥基于 EV 的治疗途径的潜力,需要解决这些问题。